AI Article Synopsis
- Cancer remains a leading cause of death, prompting research in immuno-oncology to harness the immune system to attack cancer cells.
- Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is a promising target for cancer treatment because it breaks down cGAMP, which activates the immune response.
- This study presents the first X-ray crystal structures of human ENPP1, providing crucial insights for the development of new drugs aimed at targeting this enzyme in cancer therapies.
Article Abstract
Cancer is one of the leading causes of mortality in humans, and recent work has focused on the area of immuno-oncology, in which the immune system is used to specifically target cancerous cells. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is an emerging therapeutic target in human cancers owing to its role in degrading cyclic GMP-AMP (cGAMP), an agonist of the stimulator of interferon genes (STING). The available structures of ENPP1 are of the mouse enzyme, and no structures are available with anything other than native nucleotides. Here, the first X-ray crystal structures of the human ENPP1 enzyme in an apo form, with bound nucleotides and with two known inhibitors are presented. The availability of these structures and a robust crystallization system will allow the development of structure-based drug-design campaigns against this attractive cancer therapeutic target.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466750 | PMC |
| http://dx.doi.org/10.1107/S2059798320010505 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!